Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

AML cell escape strategies involve direct adaptation of AML cells to evade immune ... Our findings offer an opportunity to further refine personalized immunotherapy regimens through genomic profiling ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN ...

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), an immunotherapy company specializing in engineered T cell therapeutics, has announced a series of strategic moves aimed at ...

Our findings thus help to address the research gap on the role of IRlncRNAs in AML and provide a novel tool to predict prognosis and plan immunotherapy interventions. There are some limitations in ...

About a third of patients with late-stage NSCLC have high levels of PD-L1 and can potentially benefit from immunotherapy. If your cancer has certain genetic mutations, immune therapy may still work, ...

Anti-KIR blocking antibodies has led to important therapeutic implications in NK cell immunotherapy ... mediated killing of HLA-matched acute myeloid leukemia blasts in vitro and in vivo.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...